LGVN logo

LONGEVERON INC-A

LGVNNASDAQ
πŸ† #4938 by market capEarnings Mar 16US Equity
$1.68β–Ό $0.22 (βˆ’11.38%)
Market closed Β· at close
πŸ””
Track LGVN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 11.4%
7dβ–Ό 32.5%
14dβ–Ό 6.4%
30dβ–² 8.1%
ytdβ–Ό 66.7%
1yβ–Ό 72.3%
🏦Market Cap
$5M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-42.7%
Declining
πŸ“ŠGross Margin
69.8%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
4.7x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.68 – $1.78
52-Week Range
$1.31 – $12.30
Volume (shares)
401
Avg Volume (shares)
β€”
Shares Outstanding
3.2M
Next Earnings
2027-03-16

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$287,000
P/E Ratio
β€”
P/S Ratio
4.7x
EPS (TTM)
$-6.72
Dividend Yield
β€”
Dilution (1yr)
+54.0%
LGVN logo

LONGEVERON INC-A

LGVN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1Mβ–Ό βˆ’49.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.0%β–Ό βˆ’15.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$23Mβ–² +40.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$19Mβ–² +27.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.3Mβ–² +54.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4Mβ–Ό βˆ’$14M YoY
StockOtter Β· stockotter.space

About LONGEVERON INC-A

Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.